ANNX — Annexin Pharmaceuticals AB (publ) Share News
0.000.00%
Last trade - 00:00- SEK55.46m
- SEK50.19m
Brief: Annexin Granted Additional Patent Protection In The Us
Brief: Annexin Resolves SEK 35.6 Mln Fully Guaranteed Rights Issue
Brief: Annexin Pharmaceuticals Q3 Net Loss Widens To SEK 10.8 Mln
Brief: Annexin Announces Success In Co's Cancer Initiative
Brief: Promising Signals Of Effect In Annexin's RVO-Study
Brief: Annexin Pharmaceuticals Q2 Loss Narrows To SEK 8.6 Mln
Brief: Annexin Pharmaceuticals Q1 Net Loss Widens To SEK 10.1 Mln
Brief: Annexin Pharmaceuticals Appoints Susanne Andersson As CFO
Brief: Annexin Pharmaceuticals Q4 Loss For Period Narrows To SEK 10.1 Mln
Brief: Annexin Pharmaceuticals Carries Out Directed Share Issue Of About SEK 7 Mln
Brief: Annexin Pharmaceuticals Q3 EBIT Loss Widens To SEK 9.6 Million
Brief: Annexin Q2 Net Loss At SEK 11.5 Million
Brief: Annexin Pharmaceuticals Q1 Net Loss Narrows To SEK 9.4 Million
Brief: Annexin: Allowance Of New U.S. Patent Covering Manufacturing Of ANXV
Brief: Annexin Signs Exclusive Licensing Deal In Cancer
Brief: Annexin Pharmaceuticals Q4 Loss SEK 15.9 Mln
Brief: University Hospital Gets Approval For Covid19-Study With Annexin Drug Candidate
Brief: Annexin Pharmaceuticals Q3 Net Loss Unchanged At SEK 8.2 Mln
Brief: Annexin Announces Outcome Of Rights Issue